[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371206-105":59,"doc-detail-371206-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","comparison-of-actionable-alterations-in-cancers-with-kinase-fusion-mutation-and-copy-number-alteration","Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration","","Kinase-related gene fusion and point mutations act as key cancer drivers, making optimized targeted therapy dependent on the specific alteration. The contribution of actionable alterations in solid tumors—particularly kinase fusions—has remained insufficiently defined. This study compared actionable alteration counts in patients with tyrosine or serine/threonine kinase domain fusions, mutations, and copy number alterations across 613 patients with 40 cancer types, and used comprehensive genomic sequencing to map actionable events.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-actionable-alterations-in-cancers-with-kinase-fusion-mutation-and-copy-number-alteration/371206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-actionable-alterations-in-cancers-with-kinase-fusion-mutation-and-copy-number-alteration/371206.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To compare the number of actionable alterations in patients with kinase-domain fusions, mutations, and copy number alterations (CNAs) across multiple solid cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients and cancer types were analyzed?",{"text":117,"@type":113},"The study analyzed 613 patients spanning 40 solid cancer types between June 2020 and April 2024.",{"name":119,"@type":110,"acceptedAnswer":120},"Which sequencing tools were used to detect alterations?",{"text":121,"@type":113},"Comprehensive genomic sequencing was performed using FoundationOne® companion diagnostic (F1CDx) and FoundationOne® Liquid companion diagnostic (F1LCDx) to detect alterations, including multi-fusion calling.",{"name":123,"@type":110,"acceptedAnswer":124},"What key pattern did the study find regarding actionable alteration counts?",{"text":125,"@type":113},"Patients with kinase fusion had significantly fewer actionable alterations than those with kinase-domain mutations and CNAs, while fusions involving tumor suppressors tended to show more actionable alterations.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},371206,1790246925,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","PLOS ONE  \nOPEN ACCESS  \nCitation: Suzuki S, Akahane T, Tanimoto A, Higashi M, Kitazono I, Kirishima M, et al. (2025)  \nComparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration. PLoS ONE 20(1): e0305025 . [https://doi](https://doi). org/10 .1371/journal.pone.0305025  \nEditor: Rama Krishna Kancha, Osmania University, Hyderabad, India, INDIA  \nReceived: May 22, 2024  \nAccepted: January 6, 2025  \nPublished: January 23, 2025  \nCopyright: © 2025 Suzuki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: The data included in this study are not publicly available to maintain patient privacy. However, the data supporting this study’s findings can be made available by the Ethics Committee and Institutional Review Board of Kagoshima University (E-mail: isgskkrs@kuas. [kagoshima-u.ac.jp](kagoshima-u.ac.jp)), upon reasonable request.  \nFunding: This work was supported by a JSPSKAKENHI grant (grant number 19K08870 to S.S.) for Clinical Research (Grant-in-Aid for Scientific Research) from the Ministry of Education, Culture,  \nRESEARCH ARTICLE  \nComparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration  \nShinsuke Suzuki1,2,3 *, Toshiaki Akahane1,4, Akihide Tanimoto4, Michiyo Higashi4, Ikumi Kitazono4, Mari Kirishima4, Masakazu Nishigaki5, Toshiro Ikeda6,  \nShuichi Kanemitsu7, Junichi Nakazawa8, Erina Akahane1, Hiroshi Nishihara9, Kimiharu Uozumi10, Makoto Yoshimitsu3, Kenji Ishitsuka3, Shin-ichi Ueno1,2  \n1 Cancer Center, Kagoshima University Hospital, Kagoshima, Japan, 2 Department of Clinical Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, 3 Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan, 4 Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, 5 International University of Health and Welfare (IUHW), Tokyo, Japan, 6 Department of Genetic Counseling, Kagoshima University Hospital, Kagoshima, Japan, 7 Department of Plastic Surgery, Sagara Hospital, Kagoshima, Japan, 8 Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan, 9 Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan,  \n10 Department of Medical Oncology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan  \n* [suzuki2@m.kufm.kagoshima-u.ac.jp](suzuki2@m.kufm.kagoshima-u.ac.jp)  \nAbstract  \nKinase-related gene fusion and point mutations play pivotal roles as drivers in cancer, necessitating optimized, targeted therapy against these alterations. The efficacy of molecularly targeted therapeutics varies depending on the specific alteration, with great success reported for such therapeutics in the treatment of cancer with kinase fusion proteins. However, the involvement of actionable alterations in solid tumors, especially regarding kinase fusions, remains unclear. Therefore, in this study, we aimed to compare the number of actionable alterations in patients with tyrosine or serine/threonine kinase domain fusions, mutations, and copy number alterations (CNAs) . We analyzed 613 patients with 40 solid cancer types who visited our division between June 2020 and April 2024. Furthermore, to detect alterations involving multiple-fusion calling, we performed comprehensive genomic sequencing using FoundationOne® companion diagnostic (F1CDx) and FoundationOne® Liquid companion diagnostic (F1LCDx) . Patient characteristics and genomic profiles were analyzed to assess the frequency and distribution of actionable alterations across different cancer types. Notably, 44 of the 613 patients had fusions involving kinases, transcriptional regulators, or tumo","cbCaib0H3du5Vrg7","https://ap.wps.com/l/cbCaib0H3du5Vrg7","pdf",782214,11,"English","# Abstract\n# Introduction\n# Methods and Analysis (implied)\n# Results (implied)\n# Conclusion (implied)","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To compare the number of actionable alterations in patients with kinase-domain fusions, mutations, and copy number alterations (CNAs) across multiple solid cancer types.\"},{\"question\":\"How many patients and cancer types were analyzed?\",\"answer\":\"The study analyzed 613 patients spanning 40 solid cancer types between June 2020 and April 2024.\"},{\"question\":\"Which sequencing tools were used to detect alterations?\",\"answer\":\"Comprehensive genomic sequencing was performed using FoundationOne® companion diagnostic (F1CDx) and FoundationOne® Liquid companion diagnostic (F1LCDx) to detect alterations, including multi-fusion calling.\"},{\"question\":\"What key pattern did the study find regarding actionable alteration counts?\",\"answer\":\"Patients with kinase fusion had significantly fewer actionable alterations than those with kinase-domain mutations and CNAs, while fusions involving tumor suppressors tended to show more actionable alterations.\"}]","Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration | PDF",1790191513,28]